Close

Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...
- Advertisement -

Simris Alg AB, a European biologics company focused on extracting high value biological active compounds from microalgae and cyanobacteria, announced a framework collaboration agreement with Lonza Ltd, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, to commercialize Simris’ ADC payload platform.

With more than 210 novel ADC clinical trials started in 2022, the market for ADC medicines continues to develop in line with their recognition as effective, stable and reliable cancer therapeutics. Novel payloads with novel modes of action, such as those developed by Simris Biologics GmbH (formally known as Cyano Biotech GmbH and a company wholly owned by Simris Alg AB), show great promise as effective cancer therapeutics that could improve quality of life for cancer patients.

Under the terms of the agreement, Lonza will integrate Simris’ ADC payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines. The Lonza Bioconjugation Toolbox comprises a range of tailored solutions for the technology selection, development, and manufacturing of bioconjugates to advance the development of novel bioconjugate-based therapies.

In return, Simris will promote Lonza to customers as its exclusive contract drug and manufacturing organization (CDMO) partner for services using its ADC technology.

Julian Read, CEO at Simris Alg AB, commented, “We are delighted that Lonza shares our confidence in the potential of our ADC payload technology. This strategic partnership will help Simris to reach new customers and Lonza’s market-leading capabilities as a CDMO increase the likelihood that our payloads will reach clinical use and thereby improve life quality for those unfortunate enough to suffer from cancer.”

Iwan Bertholjotti, Senior Director Commercial Development, Bioconjugates, Lonza Ltd, commented, “This new collaboration with Simris allows us to offer customers exclusive access to novel payloads derived from cyanobacterial natural products, as part of the Lonza Bioconjugation Toolbox. Our partnership with Simris enables us to advance the development of novel bioconjugates with the potential to transform cancer therapy and patient outcomes.”

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment

Cancer is no longer viewed solely as a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »